# US 2021/0069290 A1 · Treatment of Inflammation, Autoimmune, and Neurodegenerative Disorders with Immunosuppressive Tat Derivative Polypeptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0069290 A1
- Document ID: US20210069290A1
- Status: Published application
- Kind: A1
- Application number: 16/951,811
- Filed: 2020-11-18
- Published: 2021-03-11
- Earliest claimed: 2012-12-06
- Assignees: PIN Pharma, Inc.
- Applicants: PIN Pharma, Inc.
- Inventors: Joshua Goldberg; Colin Bier; Christoph Hotz-Behofsits; Sophie Hanscom
- Web page: https://patentgrep.com/patent/US20210069290A1

## CPC

- A61K 38/162: {from virus}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/005: from viruses
- A61K 39/21: Retroviridae, e.g. equine infectious anemia virus
- C07K 14/163: {Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx}
- C12N 2740/16311: concerning HIV regulatory proteins
- C12N 2740/16322: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present specification provides immunosuppressive Tat derivative polypeptides, compositions, and methods of using such polypeptides and compositions to treat an autoimmune disease, an inflammation-associated disease and/or a neurodegenerative disease.

## Claims

### Claim 1

An immunosuppressive trans-activator of transcription (Tat) derivative polypeptide comprising an amino acid sequence comprising the following domains in the indicated order:
a transcription factor (TF) domain comprising SEQ ID NO: 39;
a cysteine-rich region comprising SEQ ID NO: 65; and
a C-terminal region comprising amino acid residues 18-70 of SEQ ID NO: 42.

### Claim 2 (depends on 1)

The immunosuppressive trans-activator of transcription (Tat) derivative polypeptide of claim 1 comprising SEQ ID NO: 9.

### Claim 3 (depends on 1)

The immunosuppressive Tat derivative polypeptide of claim 1, wherein the TF domain further comprises a repeat sequence comprising (PVDPRLEPWKHPGSQP)n (SEQ ID NO: 12) at the N-terminus, wherein n=2-10.

### Claim 4 (depends on 1)

A pharmaceutical composition comprising the immunosuppressive Tat derivative polypeptide according to claim 1 and a pharmaceutically acceptable excipient.

### Claim 5 (depends on 4)

A method of treating a disease characterized by aberrant immune responses, the method comprising:
administering a therapeutically effective amount of the pharmaceutical composition of claim 4.

### Claim 6 (depends on 4)

A method of increasing the expression of Fas ligand (FasL) on antigen presenting cell regulatory macrophages (ARegs) comprising:
administering a therapeutically effective amount of the pharmaceutical composition of claim 4.

### Claim 7 (depends on 4)

A method of reducing inflammation, the method comprising:
administering a therapeutically effective amount of the pharmaceutical composition of claim 4.
